Lower muscle volume, and more fat stored in the muscle, are seen linked to higher risk for disease and comorbidities.

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. Barclays ...

With new systemic treatments now available for psoriatic disease, questions remain on the comparable efficacy and safety of these therapies.